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PAX3 (paired box 3) is known to have an important role in melanocyte development through modulation of microphthalmia-
associated transcription factor transcription. Here we found that PAX3 transcriptional activity could be regulated through FGF2
(basicﬁbroblastgrowthfactor)-STAT3(signaltransducerandactivatoroftranscription3)signalinginthepigmentcells.Tostudy
its function in vivo, we have generated a transgenic mouse model expressing PAX3 driven by tyrosinase promoter in a tissue-
speciﬁc fashion. These animals exhibit hyperpigmentation in the epidermis, evident in the skin color of their ears and tails. We
showed that the darker skin color results from both increased melanocyte numbers and melanin synthesis. Together, our study
delineated a novel pathway in the melanocyte lineage, linking FGF2-STAT3 signaling to increased PAX3 transcription. Moreover,
our results suggest that this pathway might contribute to the regulation of melanocyte numbers and melanin levels, and thereby
provide an alternative strategy to induce pigmentation.
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Basic ﬁbroblast growth factor (FGF2) is an important
keratinocyte-derived factor in mlenaocytes. It is known to
regulate a wide range of biological processes, such as the
development of limb and nervous system. Speciﬁcally in
melanocytes, FGF2 is essential for their proliferation in vitro.
1
However, the molecular mechanism of FGF2-induced mela-
nogenesis response remains unclear. Signal transducer and
activator of transcription 3 (STAT3) encode a transcription
factor of STAT family.
2,3 Upon stimulation by several growth
factors and cytokines, it becomes tyrosine phosphorylated
and activated by receptor-associated kinases. It regulates
diverse cellular processes through the modulation of gene
transcription. Although these two signaling proteins have
been well studied in many tissue types and biological
processes, it is unclear whether STAT3 could mediate
signaling from FGF2, especially in regulating pigmentation
in the melanocytes.
PAX3 (paired box 3) transcription factor is required for the
development of neural crest as well as several other tissue
types.
4 It modulates key regulators of melanocytes through
transcriptional activation or repression. In humans, hetero-
zygous PAX3 loss-of-function mutations are associated with
Waardenburg syndrome type I, manifesting hypopigmenta-
tion of the hair and skin, pigmentation abnormality of the iris
and premature hair graying.
4 In mice, heterozygous PAX3
mutations result in defects in multiple tissues derived from the
neural crest lineage including the patchy hypopigmentation in
skin and fur, whereas homozygosity leads to prenatal or
perinatal lethality.
5 Here we have focused our attention on
PAX3, a key transcriptional factor in the neural crest lineage
fromwhichthematuremelanocytesarise.Wesoughttobetter
understand the upstream signaling events regulating PAX3
activity and its key downstream effectors in the melanocytes,
in order to characterize its role in regulating ultraviolet (UV)B-
induced pigmentation.
We delineated a novel pathway that might contribute the
regulation of UV-induced melanogenesis. We show that this
pathway transduces signals through STAT3 from FGF2 to
PAX3.Speciﬁcally,wefoundthatUV-inducedFGF2secretion
is required in low-dose UVB-induced pigment production, and
FGF2-STAT3 signaling modulates PAX3 transcription in the
melanocytes.UponactivationbyFGF2,STAT3bindstoPAX3
upstream regulatory sequences to transactivate its promoter.
Finally, we observed that constitutive PAX3 expression in
melanocytes in vivo leads to upregulation of the melanocyte
number and melanin synthesis, which produce a hyperpig-
mentation phenotype in the epidermis of these animals.
Results
UVB treatment induces FGF2 secretion from keratinocytes.
. Previous data had suggested that the FGF2 is a paracrine factor
from keratinocytes in the UV-induced melanogenesis
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1 Speciﬁcally, this function of FGF2 is shown to be
mediated through UVB-induced FGF2 transcription in
keratinocytes.
6 To demonstrate that FGF2 secretion is also
induced by UVB exposure, we irradiated human primary
keratinocytes with UVB at 400J/m
2.W eo b s e r v e da n
induction of FGF2 section by UV that peaked at 24h and was
sustained until at least 48h (Figure 1a), consistent with FGF2’s
potential role in UVB-induced melanogenesis. In melanocytes,
multiple studies have showed that FGF2 treatment can induce
proliferation in vitro
7 and pigmented lesions in grafts.
8 Here we
reproduced FGF2 proliferative effects in our in vitro cultured
melanocytes (Supplementary Figure 1A), suggesting FGF2
might enhance pigmentation through promoting melanocyte
proliferation and maybe other mechanisms.
To test the role of FGF2 in UV-induced melanogenesis, we
used skin constructs to investigate the role of FGF2-induced
melanogenesis response. Skin reconstructs exhibits in vivo-
like morphological, ultrastructural characteristics and the
production of melanin granules, which were induced in skin
constructs with HPK and HPM by a very lose-dose UVB
irradiation (25J/m
2 per day for 3 days) and progressively
populated the layers of the tissue. Pigmentation production
was undetectable in skin reconstructs if we add PD173074, a
potent, cell-permeable and ATP-competitive inhibitor of FGF
receptor, in the culture medium (Figure 1b). However, if skin
constructs treated with PD173074 are irradiated by 100J/m
2
UVB for 4 days, we still can detect UVB-induced pigment
production (data not shown). To ensure that PD173074
completely inhibits FGFR signaling even at high UVB dose,
we examined MAPK (ERK1/2) activation in the whole protein
extracts of skin constructs.
9 This phosphorylation increase
was completely abolished in skin constructs treated with
PD173074 (Supplementary Figure 1). Together, this study
indicates that FGF2 is required in a low-dose UVB-induced
melanogenesis response, but not a high-dose UVB-induced
melanogenesis response.
FGF2 upregulates PAX3 expression in melano-
cytes. Microphthalmia-associated transcription factor
(MITF) is the key transcription regulator downstream of
MSH/MC1R signaling to promote pigment synthesis upon UV
irradiation.
10,11 We wondered whether MITF is also the
primary effector of FGF2 in melanocytes. To test this
hypothesis, we exposed primary human melanocytes to
10nmol/l FGF2 (chosen based on previous report
12) and
measured MITF mRNA and protein levels at indicated time
points after treatment. We saw a 4.5-fold induction of MITF
mRNA expression by 24h (Figure 1c). MITF protein level,
especially the phospho-MITF level, was minimally affected
by FGF2 (Figure 1c), suggesting that it is unlikely that FGF2
exerts its effects in melanocytes through promoting MITF
activity.
We then looked at the expression levels of another key
melanocyte transcriptional regulator, PAX3, upon FGF2
stimulation as previous reports have demonstrated that MITF
is directly regulated by PAX3 in the transcriptional level.
13–16
We observed a nearly 15-fold induction of PAX3 mRNA by
24h, accompanied by a marked induction of PAX3 protein
4
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Figure 1 UVB induces FGF2 secretion from keratinocytes yet MITF protein is upregulated in melanocytes. (a) FGF2 is induced by UVB in vivo. FGF2 levels were
measured by enzyme immunoassay in culture media at indicated time points. (b) The production of melanin granules, which were induced in skin constructs with HPK and
human primary melanocyte (HPM) by a very low-dose UVB irradiation (25J/m
2 per day for 3 days), and inhibited by PD173074. Fontana–Masson staining in skin constructs,
 400.(c)HPMswerestimulatedwithFGF2(10nmol/l).RNAandproteinwerecollectedattime0andatdifferenttimepointsafterstimulation.ThemRNAexpressionofMITF
wasmeasuredbyquantitativeRT-PCRandnormalizedtoGAPDH.ProteinlevelofMITF,STAT3,phosphorylatedSTAT3atTyr705andSer727,phosphorylatedERK1/2was
analyzed by western blot along with tubulin, which served a as loading control
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Cell Death and Differentiationexpression (Figure 2a). In addition, we asked whether PAX3
expression is induced by FGF2 in a dose-dependent manner
(Figure 2b). Indeed, PAX3 mRNA and protein levels are
increasingly upregulated with escalating doses of FGF2
(Figure 2b). Together, these results suggest that PAX3 could
be an important transcription factor that mediates FGF2-
induced melanogenesis.
STAT3 tyrosine phosphorylation is stimulated by FGF2
in melanocytes and important for melanocyte
proliferation. As the upregulation of PAX3 expression is
at the mRNA level upon FGF2 stimulation (Figure 2a), we
wondered which factor is transducing the signal from FGF2
to upregulate PAX3 transcripts. Previous reports have
demonstrated that FGF2 induces melanocyte proliferation,
which is mediated by MEK1/2-ERK1/2 signaling. Our studies
have conﬁrmed this conclusion (Figure 1). ERK1/2 usually
regulates the activities of several transcription factors,
including C-myc, CREB and C-Fos.
17 To identify which one
of them mediates FGF2-induced PAX3 upregulation in
melanocytes, we reduced the expression of each of them
by siRNA approach and then detected FGF2-induced PAX3
upregulation in melanocytes. Unfortunately, knockdown of
anyone of them cannot block FGF2-induced PAX3
upregulation (data not shown). Previous reports also
demonstrated that ERK family of mitogen-activated protein
kinases, but not JNK or p38, phosphorylates and activates
STAT3 in response to growth factors.
18 We therefore
detected the phosphorylation of STAT3 at tyrosine 705
(Y705) and serine 727 (S727) in melanocytes after the
stimulation of FGF2 in human primary melanocytes. Upon
FGF2 stimulation, tyrosine phosphorylation of STAT3 at
Y705 and S727 was markedly upregulated by 1h and
sustained until at least 24h (Figure 1c).
In parallel, we investigated whether the effects of FGF2 in
melanocytes were inhibited by the speciﬁc STAT3 inhibitor,
stattic
19 in human primary melanocytes. We found that FGF2-
induced melanocyte proliferation was abolished if STAT3 was
inhibited in human primary melanocytes (Supplementary
Figure 2). This result supports STAT3 being an important
downstream effector of FGF2 in regulating melanocyte
proliferation.
STAT3 activation is required for FGF2-induced PAX3
transcription. To determine whether FGF2-induced PAX3
expression is STAT3 activation dependent, we assayed
PAX3 mRNA and protein levels upon FGF2 simulation in the
presence of either STAT3 small molecular inhibitors or
siRNAs. First, we examined the effects of Stattic, a STAT3
inhibitor,
19 and FLLL31, a STAT3 phosphorylation inhibitor,
20
on the intervention of FGF2-induced STAT3 phosphorylation
and PAX3 upregulation. As shown in Figures 3a and b,
inhibition of STAT3 or STAT3 phosphorylation diminished
FGF2-induced PAX3 upregulation. These results support the
notion that the activation of STAT3 is required for the FGF2-
induced PAX3 upregulation.
Next, we explored the need for STAT3 protein in PAX3
upregulation after FGF2 stimulation using the RNAi knock-
down approach. In particular, we reduced the expression of
STAT3 by speciﬁc siRNA in B16 mouse melanoma cells
(Figure 3c) and the PAX3 expression was measured at 6h
after FGF2 stimulation. As shown in Figures 3c and d, FGF2
stimulation upregulated the expression of PAX3 in both
mRNA and protein levels in control siRNA-expressing cells.
Incontrast,similarlevelsofPAX3expressionweredetectedin
B16 cells treated with both FGF2 and siSTAT3 compared with
untreatedcontrolcells.Inotherwords,thestimulationeffectof
FGF2 was abolished in the presence of siSTAT3. Together,
these results indicate that STAT3 is required for the FGF2-
induced PAX3 upregulation.
PAX3 is a direct transcriptional target of STAT3. As
STAT3 is a transcription factor,
21,22 we wondered whether
STAT3 could mediate PAX3 mRNA upregulation through
direct transactivation of its promoter. To test this hypothesis,
we ﬁrst examined the proximal 1-kb promoter region of PAX3
12
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Figure 2 FGF2 upregulates PAX3 mRNA and protein levels in melanocytes. (a) Human primary melanocytes (HPMs) were stimulated with FGF2 (10nmol/l). RNA and
protein were collected at time 0 and at different time points after stimulation. (b) FGF2-induced PAX3 upregulation is in a FGF2 dose-dependent manner. HPMs were
stimulated with different doses of FGF2 as indicated. RNA and protein were collected at 6h after FGF2 stimulation. The mRNA expression of PAX3 was measured by
quantitative RT-PCR and normalized to GAPDH. Protein level of PAX3 was analyzed by western blot along with tubulin, which served as a loading control
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Cell Death and Differentiationto search for the consensus STAT3-binding element
(SBE).
23,24 Indeed, we found three potential general
STAT3-binding sites at  846 to  837,  769 to  760 and
 60 to  51 and one selective STAT3-binding site at  139 to
 131 in the PAX3 50-ﬂanking region B1000bp upstream of
the transcription initiation site in humans (Figure 4a). The
 60 to  51 SBE is conserved among human, monkey and
rat (Figure 4a). To further identify which SBE(s) were bound
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Figure 4 STAT3 is a direct transactivator of PAX3 promoter in melanocytes. (a) Schematic representation of the human PAX3 locus, which indicates the locations of a
STAT3-SBE that is highly conserved among human ( 60 to  51), rat ( 24 to  16) and monkey ( 60 to  51) promoters. (b) In vivo association of STAT3 with the PAX3
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Figure3 PhosphoSTAT3isrequiredforFGF2-inducedPAX3upregulation.HumanprimarymelanocytescellsweretreatedwithspeciﬁcSTAT3inhibitor,stattic(2mmol/l)
or STAT3 phosphorylation inhibitor FLLL31 (5mmol/l) together with FGF2 (10nmol/l) for 6h. Cells were processed for RNA and protein isolation. PAX3 expression was
detected by real-time PCR (a) and western blot (b). FGF2 induction of PAX3 RNA and protein are inhibited after STAT3 is inhibited or STAT3 phosphorylation is inhibited.
(b) B16 melanoma cells with siSTAT3 were stimulated with FGF2 (10nmol/l). RNA and protein were collected at 6h after stimulation. PAX3 RNA levels as measured by
quantitative RT-PCR and normalized to GAPDH (c). Protein levels of phosphorylated STAT3 at Tyr 705 were analyzed by western blot, are shown on the right along with
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Cell Death and Differentiationby STAT3 in PAX3 promoter, we performed chromatin
immunoprecipitation (ChIP) analysis. ChIPs analysis
revealed that SBEs near the transcription start site of PAX3
promoter were ampliﬁed from crosslinked chromatin isolated
from FGF2-treated human primary melanocytes and
immunoprecipitated with speciﬁc anti-STAT3 antibody, but
not from multiple controls. Furthermore, to identify which
SBE near the transcription start site of PAX3 promoter is
essential for FGF2-induced activation of PAX3 transcription,
a series of previously reported
16 PAX3-promoter-luciferase
reporters were tested for FGF2 responsiveness in B16
mouse melanoma cells. Site-speciﬁc mutation at the
evolutionarily conserved STAT3-binding site ( 60 to  51)
abolished the FGF2-induced activation of PAX3 promoter
whereas mutation at  139 to  131 site had minimal effects
on the reporter activity (Figure 4c). This data indicates that
the SBE of PAX3 promoter at  60 to  51 from the
transcriptional start site mediates its transactivation by
STAT3. Together, these data suggest that STAT3 directly
modulates activation of the PAX3 promoter.
Constitutive PAX3 expression in melanocytes leads to
hyperpigmentation in vivo. To further address the role of
PAX3 in melanocytes in vivo, we generated a transgenic
mouse with melanocyte-speciﬁc PAX3 expression under the
control of tyrosinase (Tyr) enhancer/promoter (Figure 5a).
The PAX3 expression construct was designed such that the
PAX3 gene (NM_181457), cloned from human primary
melanocytes, was inserted into the vector (pNEB 193)
downstream of the murine tyrosinase locus control region
(enhancer/promoter) (Figure 5a). This construct was injected
into single-cell embryos of F1 C57BL/J6XCBA mice and the
offspring were genotyped by Southern blot analysis
(Figure 5b) and PCR (Figure 5c). One founder line was
studied in detail, in which the relative protein expression level
of the PAX3 transgene is nearly equal in comparison to the
endogenous protein level in the epidermis of neonatal mice
(Figure 5d). RT-PCR analysis shows that the transgene was
expressed in the skin and brain, but not in the heart, kidney,
lung or liver (Figure 5e), with the expression in the skin
resulting most likely from expression in melanocytes. In
comparison with wild-type C57BL/J6XCBA mice, the animals
that overexpressed PAX3 have hyperpigmented skin, most
evident in the ear pinnae and tail, but normal coat color
(Figure 5f). Epidermal melanin assay demonstrated that
hyperpigmentation was consequent to an increased melanin
production (Figure 5g). Furthermore, no melanoma was
diagnosed in transgenic PAX3 mice to date (24 week old).
To identify whether melanin production is a result from
melanocyte proliferation, differentiation or both, we used
FACS analysis to isolate and quantify melanocytes from
mouse epidermis. The Anti-Trp2 antibody was used as a
marker of melanocyte and conﬁrmed by anti-CD31 anti-
body.
25,26 To detail the melanocyte populations expressing
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Figure 5 Hyperpigmentation was detected in transgenic PAX3 mouse. (a) Schematic diagrams of Tyr-PAX3 construct. (b) Southern blot analysis of transgene. (c) PCR
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FGF2-STAT3-PAX3 signaling in melanogenesis
L Dong et al
620
Cell Death and Differentiationthe transgene, PAX3 expression was tested by immunohis-
tochemical staining in hair follicles and epidermis of wild-type
andPAX3-tgmice.Inhairfollicles,thePAX3-speciﬁcantibody
showed stronger nuclear staining in PAX3-tg mice than in
wild-type mice (Supplementary Figure 3). As shown in
Figure 5h, the number of epidermal melanocytes is signiﬁ-
cantly higher in PAX3-tg mice than in wild-type mice (Z1.5-
fold). Together, these results support the notion that
hyperpigmentation in PAX3-tg mice is caused by PAX3-
induced melanocyte hyper-proliferation and increased
melanin synthesis. More importantly, this experiment
demonstrated that PAX3 gain-of-function enhances pigmen-
tation in vivo.
Discussion
Here we delineate a new signaling pathway in UVB-induced
melanogenesis response. In this signaling pathway, UVB
radiation stimulates FGF2 protein secretion from human
keratinocytes, which in turn induces PAX3 transcription
through activation of STAT3 in melanocytes. Speciﬁcally, we
showed that PAX3 is regulated by STAT3 protein at the
transcriptional level directly (Figure 6).
Here we found UVB radiation stimulated FGF2 protein
secretionfromhumankeratinocytes,andFGF2isrequiredina
low-dose UVB-induced pigment production, but not in a high-
doseUVB-inducedpigmentproduction.WeshowedthatFGF2
augmented PAX3 transcription through activation of STAT3 in
melanocytes. These results also indicate that alternative
signaling pathways are induced in an UVB-dose-dependent
manner. It remains to be determined whether other signaling
pathways could also modulate pigment induction upon UV
exposure and to what extend each pathway contributes to
the phenotype. Importantly, identiﬁcation and comprehensive
characterization of these pathways could help to build the
entire signaling network linking the external stimulus (i.e. UV
irradiation) to the eventual biological outcomes (i.e. pigmenta-
tion and prevention/repair of UV damage).
ChIP revealed that the STAT3 protein speciﬁcally occupies
the endogenous PAX3 promoter after FGF2 stimulation in
human primary melanocytes. Our previous report has
demonstrated that the  200bp relative to the transcription
start site of PAX3 is crucial for regulating PAX3 transcrip-
tion.
16 In this region of PAX3 promoter, a Smad-binding
element( 85to 107)
16 anda myc-binding element( 110to
 105)
27 were identiﬁed. Here, we further identiﬁed a SBE
( 60 to  51) in this region. Other critical transcriptional
regulatory regions in PAX3 promoter include binding sites for
POU transcription factors at  1359 to  1334 and  856 to
 827,
28,29 and Teads transcription factors at NCE1 and
NCE2 (both around  1600
30 relative to the transcription start
siteofPAX3).Thecontributionofeachtranscriptionfactorand
their interactions in the regulation of PAX3 transcription,
especially after UV radiation, should be further characterized.
STAT3 is a known downstream effector of several growth
factor receptors.
2,3 It has been shown that FGF2 could
activate STAT3 in some cellular contexts.
31–33 Yet it remains
unclear whether STAT3 directly associates with FGFRs, or if
itsactivationismediatedthroughcross-talkbetweensignaling
pathways. STAT3 regulates the transcription of genes with
diverse functions, including immunity, apoptosis, angiogen-
esis and proliferation.
2 Here we found that upon FGF2
simulation, STAT3 becomes activated and in turn directly
transactivatesPAX3promoterinmelanocytes.Inotherwords,
our results identiﬁed PAX3 as a novel direct target of STAT3,
suggested a novel function of STAT3 in the pigment cell
lineage, and broadened our understanding of the transcrip-
tional network involved in regulation of melanogenesis.
To better understand the role of PAX3 in differentiated
melanocytes, we have generated a transgenic mouse model
in which PAX3 transgene expression is under the control of
tyrosine promoter. There was a twofold increase in the PAX3
protein level in the transgenic mice. Importantly, we observed
hyperpigmentation in the skin of these mice resulting from
both increased melanocyte cell number and increased
pigment production. These results suggest that PAX3 indeed
promotes proliferation and stimulates melanin synthesis in
mature melanocytes, independent of its known role during
melanocyte development. These observations also support
the hypothesis that PAX3 could contribute to pigment
induction upon UVB irradiation in these cells.
16 Together, this
mouse model provides an excellent tool to understand PAX3
function in differentiated melanocytes in vivo.
Materials and Methods
Cell lines, reagents and UV exposure. Primary keratinocytes and
melanocytes were isolated from normal discarded foreskins as described.
34,35
FGFb (FGF2), Stattic and FLLL31 were purchased from Sigma (St. Louis, MO,
USA). Short hairpin RNA duplexes that target PAX3 were purchased from Origene
(Rockville, MD, USA) and described elsewhere.
16
Reconstructed skin. Skin reconstructs were generated using MelanoDerm
(MatTek Corp., Ashland, MA, USA) with modiﬁcations.
Generation of PAX3 transgenic mice. The mouse tyrosinase enhancer,
promoter and SV40 poly-A tail was purchased from Addgene (Cambridge, MA,
USA) and originally generated by Dr. Marcus at Dr. Lynda Chin’s lab (Dana Farber
Cancer Institute,Boston, MA, USA). Human PAX3 cDNA was inserted downstream
of the tyrosinase enhancer promoter. The DNA construct was gel puriﬁed (Qiagen,
Valencia, CA, USA), sequenced and microinjected into single-cell embryos of F1
C57BL/6 mice at Transgenic Core Facility of Boston University.
A low dose UV radiation
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Figure 6 Schematic diagram of the FGF2-STAT3-PAX3 signaling pathway
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Cell Death and DifferentiationMelanin concentration detection. Mouse ear epidermal separation was
described elsewhere.
36 The epidermis was treated with 0.5% sodium dodecyl
sulfatein0.05MTrisbuffer(pH7.0)containing2mg/mlPronase-CB.Mixtureswere
incubated at 301C for 24h. The digests were collected by centrifuge (10000 g
for 30min). Melanin was obtained by centrifugation and washing three times with
4ml KCI solution (0.01%) and then solutes it in 0.1N NaOH. The melanin content
was detected by spectrophotometer at absorbance 400nm.
37,38
Western blotting. Western blotting was performed using the following anti-
bodies: anti-PAX3 (The Developmental Studies Hybridoma Bank at the University of
Iowa, Iowa, IA, USA); anti-MITF (C5, generously provided by Dr. David E Fisher at
Massachusetts General Hospital, Boston, MA, USA); anti-p-STAT3 (Tyr705) (Cell
Signaling, Beverly, MA, USA); anti-p-STAT3 (Ser727) (Cell Signaling); anti-STAT3
( 9 D 8 ,T h e r m oS c i e n t i ﬁ c ,B e v e r l y ,M A ,U S A ) ;a nti-p-ERK1/2 (Cell Signaling); and anti-
tubulin (Sigma).
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